For adults with moderately to severely active ulcerative colitis (UC).
A DUAL-ACTING
TREATMENT*†
1
TREMFYA® targets IL-23, a key component of inflammation in UC.*†
2
TREMFYA® also binds to a target on the cells that make IL-23 called CD64.†‡
*Based on laboratory experiments using inflammatory cells.
†The clinical significance of these findings is unknown.
‡CD64 are proteins on the surface of certain immune cells, and these cells are the main producers of IL-23 in UC. Cells that do not have CD64 on their surface may also produce IL-23, but to a lesser extent.
”Only” based on approved selective IL-23 inhibitors for moderately to severely active UC as of September 2024.
CD64=cluster of differentiation 64; IL=interleukin.
Find a nearby doctor who treats UC
Use this HealthgradesTM tool to easily find nearby specialists with experience in treating adults with moderately to severely active ulcerative colitis (UC).
